iNGENū CRO, a global contract research organization, has set out the main operational factors it says enable sponsors to run clinical trials at lower cost while meeting international regulatory standards.
The company said the approach combines the use of cost-efficient global trial locations, access to government R&D incentive programs and the adoption of modern trial technologies intended to streamline monitoring and data collection.
Global Trial Locations
iNGENū CRO conducts trials in jurisdictions that adhere to ICH-GCP requirements, with data accepted by major regulators including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
These markets offer established ethics review processes, experienced investigators and lower overhead than traditional U.S. and European trial centres, the company said.
Government Incentives
Several of the regions in which the company operates provide R&D tax incentives or grant schemes that can offset clinical development costs. These programs reduce net expenditure for sponsors without adding regulatory complexity, by virtue of a Government bursary.
Decentralized Clinical Trial Design and Technology
The company also uses decentralized clinical trial (DCT) models to reduce reliance on physical sites, enabling remote data capture and patient engagement.
Risk-Based Monitoring (RBM) frameworks are applied to focus oversight on areas of higher operational risk, reducing the need for extensive on-site verification.
iNGENū CRO said its integrated digital platforms support protocol management, data capture and compliance oversight.
“Our objective is to provide an efficient clinical trial model that maintains scientific and regulatory standards while reducing unnecessary cost,” said Dr. Sud Agarwal, chief executive officer of iNGENū CRO. “By combining global site strategy, modern monitoring methods and government incentives, sponsors can run trials more efficiently.”
Media Contact
Amanda DeVito
press@ingenuCRO.com
